Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Yamamoto N, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Tanabe Y, Horiike A, Yanagitani N, Kitazono S, Inatani M, Tanaka J, Nishio M. Yamamoto N, et al. Among authors: yanagitani n. Invest New Drugs. 2017 Feb;35(1):37-46. doi: 10.1007/s10637-016-0382-3. Epub 2016 Aug 27. Invest New Drugs. 2017. PMID: 27565810 Clinical Trial.
Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Kaira K, Sunaga N, Yanagitani N, Kawata T, Utsugi M, Shimizu K, Ebara T, Kawamura H, Nonaka T, Ishikawa H, Sakurai H, Suga T, Hara K, Hisada T, Ishizuka T, Nakano T, Mori M. Kaira K, et al. Among authors: yanagitani n. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):109-14. doi: 10.1016/j.ijrobp.2008.06.1938. Epub 2008 Oct 15. Int J Radiat Oncol Biol Phys. 2009. PMID: 18929446 Clinical Trial.
Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
Kaira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Iwasaki Y, Shimizu K, Iijima H, Tsurumaki H, Tomizawa Y, Hisada T, Ishizuka T, Saito R, Mori M. Kaira K, et al. Among authors: yanagitani n. Lung Cancer. 2010 May;68(2):253-7. doi: 10.1016/j.lungcan.2009.06.024. Epub 2009 Jul 23. Lung Cancer. 2010. PMID: 19631403 Clinical Trial.
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K. Sakai K, et al. Among authors: yanagitani n. Cancer Sci. 2013 Sep;104(9):1198-204. doi: 10.1111/cas.12211. Epub 2013 Jul 1. Cancer Sci. 2013. PMID: 23721103 Free PMC article.
A phase II study of S-1 in relapsed small cell lung cancer.
Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Tahanaka H, Yanagitani N, Saito R, Kaburaki K, Sakatani T, Horai T, Nishio M. Kudo K, et al. Among authors: yanagitani n. Mol Clin Oncol. 2013 Mar;1(2):263-266. doi: 10.3892/mco.2013.67. Epub 2013 Jan 14. Mol Clin Oncol. 2013. PMID: 24649158 Free PMC article.
159 results